XOMA Royalty (XOMA) Capital Expenditures (2010 - 2024)

XOMA Royalty's (XOMA) quarterly Capital Expenditures came in at $3000.0 in Q4 2024, down 82.35% quarter-over-quarter from $17000.0 in Q1 2024.

XOMA Royalty (XOMA) Capital Expenditures (2010 - 2024) Analysis & Trends

XOMA Royalty has disclosed Capital Expenditures across 9 years of filings, most recently posting $3000.0 for Q4 2024.

Capital Expenditures for Q4 2024 came in at $3000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $20000.0 (changed N/A YoY), and the FY2024 annual result was $20000.0, up 17.65% from the prior year.
Capital Expenditures came in at $3000.0 for Q4 2024 at XOMA Royalty, down from $17000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $17000.0 in Q1 2024 to a low of $3000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	133.40 Mn
9	Abivax	95.45 Bn	95.45 Bn	-	-63,220.27
10	XOMA Royalty	5.52 Mn	-60.56 Mn	-	-

Download Data